Abstract
Lifestyle intervention prevents or delays the conversion from impaired glucose tolerance (IGT) to type 2 diabetes. However, many subjects fail to achieve and/or maintain long-term weight loss and to follow a regular exercise regimen may require pharmacologic therapy. Insulin resistance in liver, muscle and fat, along with impaired beta-cell function, plays a central role in the pathogenesis of type 2 diabetes. Insulin sensitising drugs, including metformin and the thiazolidinediones, have significantly reduced the conversion rate of IGT to type 2 diabetes in subjects in several large, well designed clinical trials. Insulin-sensitising drugs are likely to play an important role in future strategies for diabetes prevention.
| Original language | English (US) |
|---|---|
| Pages (from-to) | S24-S40 |
| Journal | British Journal of Diabetes and Vascular Disease |
| Volume | 3 |
| Issue number | SUPPL. 1 |
| DOIs | |
| State | Published - 2003 |
Keywords
- Beta-cell dysfunction
- Impaired glucose tolerance
- Insulin resistance
- Metformin
- Thiazolidinediones
- Type 2 diabetes
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Cardiology and Cardiovascular Medicine
Fingerprint
Dive into the research topics of 'Impaired glucose tolerance: Do pharmacological therapies correct the underlying metabolic disturbance?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS